KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) FCF Margin (2016 - 2025)

Historic FCF Margin for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to 48.17%.

  • Halozyme Therapeutics' FCF Margin fell 107000.0% to 48.17% in Q4 2025 from the same period last year, while for Dec 2025 it was 46.15%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 46.15% for FY2025, which is 200.0% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported FCF Margin of 48.17% as of Q4 2025, which was down 107000.0% from 49.56% recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year FCF Margin high stood at 104.67% for Q3 2021, and its period low was 23.0% during Q2 2024.
  • Its 5-year average for FCF Margin is 48.58%, with a median of 44.99% in 2023.
  • In the last 5 years, Halozyme Therapeutics' FCF Margin surged by 956300bps in 2021 and then plummeted by -718300bps in 2022.
  • Halozyme Therapeutics' FCF Margin (Quarter) stood at 80.74% in 2021, then tumbled by -46bps to 43.36% in 2022, then increased by 0bps to 43.37% in 2023, then surged by 36bps to 58.86% in 2024, then fell by -18bps to 48.17% in 2025.
  • Its last three reported values are 48.17% in Q4 2025, 49.56% for Q3 2025, and 30.13% during Q2 2025.